expansion – Page 8

AstraZeneca’s Ambitious Vision: Pursuing $80 Billion in Revenue and 20 New Drugs by 2030

2 years ago talkbio0Tagged AstraZeneca, Biotechnology, Drug Development, Drug Industry, expansion, growth strategy, healthcare innovation, Market

AstraZeneca, revenue target, new drugs, 2030, growth strategy, pharmaceutical industry, healthcare innovation, biotechnology, drug development, market expansion.

AstraZeneca Invests $1.5 Billion in Singapore for State-of-the-art Antibody-Drug Conjugate Manufacturing Facility

2 years ago talkbio0Tagged Antibody-Drug Conjugates, AstraZeneca, Biotechnology, Cancer Therapeutic Procedure, end-to-end, expansion, Facility (object), Generalized, innovation, Investments, Singapore

AstraZeneca, Singapore, investment, antibody-drug conjugate (ADC), manufacturing facility, end-to-end production, biotechnology, pharmaceuticals, cancer treatment, innovation, global expansion.

Rapport Neuroscience Biotech Aims for Expansion with Initial Public Offering

2 years ago talkbio0Tagged clinical-stage, expansion, IPO, mental health, nervous system disorder, Neuroscience discipline, Rapport

Rapport, neuroscience, biotech, IPO, clinical-stage, expansion, pharmaceuticals, neurological disorders, mental health

Galapagos Expands Decentralized CAR-T Manufacturing Across the Nation with Strategic Partnership

2 years ago talkbio0Tagged Biotechnology, Cancer Therapeutic Procedure, CAR-T, decentralized, expansion, Galapagos, healthcare innovation, Immunotherapy, Manufacture, nationwide, Partnership

Galapagos, decentralized CAR-T manufacturing, partnership, nationwide expansion, cancer treatment, immunotherapy, biotechnology, healthcare innovation.

Johnson & Johnson Expands into IL-13 and TSLP Market with Strategic Acquisition

2 years ago talkbio0Tagged Acquisition (action), Biological Factors, competition, Drug Industry, expansion, I&I, Inflammatory disorder, Interleukin-13, Johnson and Johnson, Market, strategic, TSLP gene

Johnson & Johnson, I&I acquisition, IL-13, TSLP, competitive market, strategic expansion, pharmaceutical industry, biologics, inflammatory diseases.

FDA Rejects Dynavax’s Heplisav-B Expansion Due to Data Gaps

2 years ago talkbio0Tagged Dynavax, expansion, Hepatitis B, Heplisav-B, Rejection (Psychology), United States Food and Drug Administration, Vaccines

FDA, Dynavax, Heplisav-B, data gaps, rejection, expansion, vaccine, hepatitis B

Ono Pharmaceutical Strengthens Oncology Portfolio with Acquisition of Deciphera Pharmaceuticals for $2.4 Billion

2 years ago talkbio0Tagged Acquisition (action), cancer treatments, Clinical Development, Collaboration, Deciphera, Dosage Forms, expansion, Generalized, Market, Oncology Pipeline, strategic

Ono Pharmaceutical, Deciphera Pharmaceuticals, oncology pipeline, acquisition, $2.4 billion, cancer treatments, kinase inhibitors, strategic expansion, global market, clinical development, collaboration.